Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.
Jean-Charles Soria
Honoraria - Abbott Laboratories; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EOS; Genentech; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche; Sanofi
Hui Kong Gan
No relevant relationships to disclose
Hendrik-Tobias Arkenau
No relevant relationships to disclose
Sarah Patricia Blagden
No relevant relationships to disclose
Ruth Plummer
No relevant relationships to disclose
Malcolm Ranson
No relevant relationships to disclose
T.R. Jeffry Evans
No relevant relationships to disclose
Gerard Zalcman
No relevant relationships to disclose
Rastislav Bahleda
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Charlotte Lemech
No relevant relationships to disclose
Jennifer Brown
No relevant relationships to disclose
Vijay Gopal Reddy Peddareddigari
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Diana Gibson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Sharon Cornell Murray
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Noelia Nebot
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Jolly Mazumdar
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ronald Alan Fleming
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael Millward
No relevant relationships to disclose